Dr. Zhou is Director, Pediatric Translational Medicine Insititute; Chair, Department of Pharmacology and Chemical Biology, Shanghai Jiaotong University School of Medical. Current research interests include DDR as a barrier for childhood leukemia relapse, interaction between DDR and purine biosynthesis pathway. The first part of the study was published as a cover story in Nature Medicine in 2015.
He has been interested in cancer drug discovery and drug resistance mechianism over the years, and has contributed to one approved, one phase III and two phase II clinical trial anti-cancer agents. In academic community, he is best known for his proposal of DNA damage response (DDR) hypothesis in collaboration with Dr. Stephen Elledge. He received BS from Fudan University, PhD from University of California, Berkeley, and was a postdoctoral fellow with Marc Kirschner at Harvard Medical School. He received many awards including UC Berkeley University Fellowship, Helen Hay Whitney Fellowship, SAPA (Sino-American Pharmaceuticals Professional Association) Achievement Award.